Home / Market News / $DXCM
fiscal.ai Corporate Catalyst Impact 65/100 ● neutral

Analysts Adjust Price Targets for DexCom, Inc.

Oct 30, 2026, 1:35 PM UTC · Primary ticker $DXCM

Multiple financial institutions, Raymond James and Barclays, have increased their price targets for DexCom, Inc. stock. This positive adjustment follows DexCom's strong third-quarter 2026 earnings report and an upward revision of its full-year revenue guidance, indicating improved analyst sentiment and potential for stock appreciation.

Raymond James and Barclays have both raised their price targets for DexCom, Inc. stock, moving to $97 from $94 and $120 from $115, respectively. This positive re-evaluation by analysts is a direct consequence of DexCom's recent third-quarter 2026 earnings report, which not only met but also exceeded expectations, leading the company to increase its full-year 2026 revenue guidance. This news is primarily positive for DexCom shareholders, as it signals growing confidence from institutional investors and could attract further buying interest, potentially driving the stock price higher in the short term. The long-term implication is a reinforced positive outlook for the company's financial performance and market position. A key opportunity for traders is to consider the potential for continued upward momentum in DXCM shares, driven by this renewed analyst optimism and strong underlying business performance.

$DXCM positive Increased price targets and revenue guidance
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.